Firstline treatment for hepatitis C: Combination interferon/ribavirin versus interferon monotherapy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 15, Issue SUPPL. MAY, 2000, Pages

  Lai, Ming Yang ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; RIBAVIRIN; VIRUS DNA; VIRUS RNA;

ANEMIA; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; HEPATITIS C; HUMAN; IMMUNOTHERAPY; LIVER CIRRHOSIS; LIVER HISTOLOGY; MONOTHERAPY; PRIORITY JOURNAL; VIREMIA; VIRUS GENOME;

EID: 0033919942     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2000.02136.x     Document Type: Article

References (26)

1. World Health Organization. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp Belgium. Global surveillance and control of hapatitis C. J. Viral Hepatitis 1999; 6: 35-47.
2. Kiyosawa K, Sodeyama T, Tanaka E et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671-5.
3. Poynard T, Bedossa P, Opolon P et al. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-32.
4. Araya V, Rakela J, Wright T. Hepatitis C after orthotopic liver transplantation. Gastroenterology 1997; 112: 575-82.
5. Lindsay KL. Therapy of hepatitis C: an overview. Hepatology 1997; 26 (Suppl. 1): S71-7.
6. Chemello L, Cavalletto L, Bernardinello E, Guido M, Pontisso P, Alberti A. The effect of interferon alfa and ribavirin combination therapy in naïve patients with chronic hepatitis C. J. Hepatol 1995; 23 (Suppl. 2): 8-12.
7. Lai MY, Kao JH, Yang PM et al. Long-term efficacy of ribavirin plus interferon in the treatment of chronic hepatitis C. Gastroenterology 1996; 111: 1307-12.
8. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alfa-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83-7.
9. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 1998; 339: 1485-92.
10. Poyard T, Marcellin P, Lee SS et al. Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-32.
11. Davis GL, Estaban-Mur R, Rustgi V et al. Retreatment of relapse after interferon therapy for chronic hepatitis C. An international randomized controlled trial of interferon plus ribavirin vs interferon alone. N. Engl. J. Med. 1998; 339: 1493-9.
12. Poynard T, Leroy V, Cohard M et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects, dose, duration. Hepatology 1996; 24: 778-89.
13. National Institute of Health Consensus Development Conference Panel Statement. Management of hepatitis C. Hepatology 1997; 26 (Suppl. 1): 25-105.
14. Marcellin P, Levy S, Erlinger S. Therapy of hepatitis C. Patients with normal aminotransferase levels. Hepatology 1997; 26 (Suppl. 1): 1335-65.
15. Camma C, Giunta M, Pinzello G, Morabito A, Verderio P, Pagliaro L. Chronic hepatitis C and interferon alpha: Conventional and cumulative meta-analyses of randomized controlled trials. Am. J. Gastroenterol. 1999; 94: 581-95.
16. Lin R, Roach E, Zimmerman M et al. Interferon alfa-2b for chronic hepatitis C effects of dose increment and duration of treatment on response rates: Results of first multicenter Australian trial. J. Hepatol. 1995; 23: 487-96.
17. Shiratori Y, Kato N, Yokosuka O et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Gastroenterology 1997; 113: 558-66.
18. Karino Y, Toyota J, Sugawara M et al. Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C. Am. J. Gastroenterol. 1997; 92: 61-5.
19. Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 1998; 282: 103-7.
20. Layden TJ, Lam NP, Wiley TE. Hepatitis C viral dynamics. Clin. Liver Dis. 1999; 3: 793-810.
21. Shiffman M, Pockros PJ, Reddy RK et al. A controlled, randomized, multicenter, descending dose phase II trial of pegylated interferon alfa-2a (PEG) vs standard interferon alfa-2a (IFN) for treatment of chronic hepatitis C. Gastroenterology 1999; 116: (DDW (Abstract) L418).
22. Heathcote J, Shiffman ML, Cooksley G et al. Multinational evaluation of the efficacy and safety of once-weekly peginterferon α-2a (PEG-IFN) in patients with chronic hepatitis C (CHC) with compensated cirrhosis. Hepatology 1999; 30: 316A.
23. Reichard O, Andersson J, Schvarcz R et al. Ribavirin treatment for chronic hepatitis C. Lancet 1991; 337: 1058-61.
24. Bodenheimer HC, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C. A multicenter trial. Hepatology 1997; 26: 473-7.
25. Schalm SW, Weiland O, Hansen BE et al. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: Analysis of individual patient data of six controlled trials. Gastroenterolgy 1999; 117: 408-13.
26. EASL. International Consensus Conference on Hepatitis C. J. Hepatol. 1999; 30: 956-61.